Cyclerion Therapeutics, Inc. (CYCN) Stock

Cyclerion Therapeutics, Inc. (CYCN) is a Healthcare stock trading at $3.89 (as of 2026-08-21), with a market capitalization of $18.21M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and related diseases. Its pipeline includes CY6463 for mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes, and Alzheimer’s disease with vascular pathology, as well as Praliciguat, Olinciguat, and CY3018 in clinical studies for specific indications.

Understand Cyclerion Therapeutics, Inc.: how it makes money

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines for serious central nervous system (CNS) diseases, primarily through advancing its pipeline candidates through clinical trials.

For a clinical-stage CNS biopharma, profit potential is structurally driven by whether lead candidates like CY6463 successfully progress through clinical development and reach commercialization for specific CNS indications.

Business quality (Weak): Pipeline progress is clearly the focus, but the provided facts do not include segment revenue detail or operating KPIs, limiting how specifically an investor can track execution beyond trial stage.

Bull case

  • Lead asset has multiple clinical readouts across CNS diseases: CY6463 is in Phase IIa trials for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, and for Alzheimer's disease with vascular pathology. It is also in Phase 1 trials for schizophrenia in adults.
  • Clear CNS specialization in both development and pipeline focus: The company is focused on discovering, developing, and commercializing medicines for serious central nervous system (CNS) diseases.

Bear case

  • Clinical-stage execution risk: The provided information shows CY6463 is in Phase IIa and Phase 1, which implies outcomes are still being tested before commercialization.
  • Loss-making operations in the latest quarter shown: For the period ending 2025-09-30, operating margin is reported as -115.0, indicating significant operating losses.
Valuation — source: SEC EDGAR (first-party)
Price$3.89
Market Cap$18.21M
Price / Book3.58
Price / Sales20.81
FCF Yield-28.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.07M
Net Margin-170.1%
Revenue Growth (YoY)3.7%
EPS Growth (YoY)-8.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-27.76 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSiren, L.L.C. ($146816.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORegina Graul
Employees1
CountryUS
IPO Date2019-03-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Marker Therapeutics, Inc. (MRKR)
  • Biofrontera Inc. (BFRI)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Celularity Inc. (CELU)
  • Palatin Technologies, Inc. (PTN)
  • Tvardi Therapeutics, Inc. (TVRD)
  • Tempest Therapeutics, Inc. (TPST)
  • KALA BIO, Inc. (KALA)
CYCN earnings history · CYCN institutional & insider holders · CYCN KPIs & operating metrics · CYCN financials · CYCN investor presentations & press releases · CYCN SEC filings · CYCN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.